Home > IP News
Here’s a patent gambit for you: Roche’s Genentech unit sued Eli Lilly for infringement Tuesday, claiming the Indianapolis drugmaker’s psoriasis drug Taltz steps on one of its patents.
Thing is, Genentech just won that patent this week.
Taltz has been on the market since 2016—long enough to build up to $486 million in U.S. sales last year, despite heavy competition in its field from Novartis’ first-to-market Cosentyx and other newcomers. But Genentech alleges that the drug, which works by inhibiting the immunology pathway IL-17, infringes its own brand-new patent that covers biological drugs that target that specific pathway.